Lupin Gets USFDA Nod for Generic HIV Drug

Share:    

Feb 03, 2025 15:54

Lupin has received USFDA approval for its generic version of Symtuza, a medication for HIV. The product is estimated to have annual sales of USD 1.374 billion in the US.
Lupin Gets USFDA Nod for Generic HIV Drug
New Delhi, Feb 3 (PTI) Drug maker Lupin on Monday said it has received approval from the US health regulator to market a generic medication for Human Immunodeficiency Virus.

The company has received tentative approval from the US Food and Drug Administration (USFDA) for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets, the company said in a statement.

The company's product has been found to be therapeutically equivalent to the reference listed drug Symtuza tablets, 800 mg/150 mg/200 mg/10 mg of Janssen Products, LP, it added.


Lupin is the exclusive first-to-file for this product, it stated.

As per the IQVIA MAT December 2024 data, Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets had estimated annual sales of USD 1,374 million in the US.

Shares of Lupin were trading 1.29 per cent down at Rs 2,028.70 apiece on BSE.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback